Market View 20th May, 2026

View on market: Volatility persists, eagerly searching for growth:

Global markets remained under pressure on Wednesday as rising geopolitical tensions and higher bond yields weighed on investor sentiment. Asian markets traded lower after fresh remarks from US President Donald Trump regarding Iran increased uncertainty in global markets. Japan and South Korea markets also ended weak, with technology and small-cap stocks seeing sharper selling. US markets extended losses for a third straight session as concerns over inflation and rising yields continued to impact sentiment. Technology stocks remained volatile ahead of key earnings from chipmaker Nvidia, which kept investors cautious. Indian benchmark indices ended slightly lower after moving in a narrow range throughout the session. Weak global cues and cautious investor mood kept markets under pressure, though losses remained limited compared to other major markets.

Key Quarterly Results for Today:

ACE, APOLLOHOSP, ARVSMART, BOSCHLTD, CAPACITE, CARYSIL, CITYSQUARE, DCMSRIND, EPACK, GPTINFRA, GRASIM, HITECHCORP, IGIL, INDOTECH, INTEGRAEN, JKLAKSHMI, JNKINDIA, JUBLFOOD, KEIL, KRONOX, LENSKART, METROBRAND, MOSCHIP, MOTHERSON, OLAELEC, POWERMECH, SAMMAANCAP, SRMENERGY, TALBROAUTO, WHIRLPOOL.

Economic Calendar:

• USD: FOMC Minutes on 20^th May 2026.
• IND: Infrastructure Output Data on 20^th May 2026.
• USD: Continuing & Initial Jobless and S&P Global Composite & Manufacturing & Services PMI Data on 21^st May 2026.
• IND: HSBC Composite & Manufacturing & Services PMI Data on 21^st May 2026.

BROKERAGE RADAR:

MORGAN STANLEY ON BLACKBUCK:

Maintain Equal-weight with target price of ₹650, Q4: Beat on top line; adjusted EBITDA missed consensus sightly, Profitability in core business is consistent, Vehicle Finance close to EBITDA break-even, Near-term caution on outlook with West Asian conflict’s impact on freight movement and loyalty program temporarily discontinued by the OMCs.

CITI ON ICICI BANK:

Maintain Buy with target price of ₹1720, Broad-based growth momentum led by step-up in retail, Corporate growth supported by a structural shift in funding from bond markets to banks, NIMs range-bound with mix optimization the lever, while CoD may remain elevated, West Asia crisis shows no visible portfolio stress; actively monitoring borrowers exposed to global trade and supply chain disruptions.

CITI ON AXIS BANK:

Maintain Buy with target price of ₹1620, West Asia crisis – No visible deterioration and remains comfortable on growth and asset quality;, Carries sufficient buffer to absorb most adverse scenario, Disciplined growth strategy: To outperform system average growth, Committed to through-the-cycle NIM of 3.8% given structural levers, Expect some near-term NIM pressure from the mix shift.

MORGAN STANLEY ON MANKIND PHARMA:

Target ₹2500, EBITDA led by healthy domestic growth, Healthy double-digit domestic growth backed by key therapy growth performance, Maintain stance on Mankind given its improved domestic growth recovery.

International Markets:

U.S & Europe:

*As per 20^th May.

Asian markets:

Stocks strong on Chart:

Commodities & Currency:

FIIs & DIIs:

View on market: Volatility persists, eagerly searching for growth

News Updates:

Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited (Elite Wealth Limited is wholly owned subsidiary of InCred Capital Financial Services Limited) does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

1. All of the views expressed in the report accurately reflect his or her personal views about any and all of

the subject securities or issuers; and

2. No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal

Entities Disclosures

Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
3. EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
4. EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
5. Compensation
6. EWL  or its associates have not received any compensation from the subject company in the past twelve months;
7. EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
8. EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
9. EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
10. EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research
11. In respect of Public Appearances
12. EWL or its associates have not received any compensation from the subject company in the past twelve months;
13. The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL